Table 1. Patients features of the included patients.

Items		n		FN		no-FN		P
				n	%	n	%
Age (yrs, Mean±std)		47.3±9.8		45.9±9.3		47.5±9.9		NS
BMI (Mean±std)		23.2±4.0		22.7±3.8		23.3±4.0		NS
BSA (m∧2 Mean±std)		1.6±0.2		1.52±0.2		1.56±0.2		NS
Hypertension history
No		386		54	14	332		<0.05
Yes		41		1	2	40	98
Diabetes history
No		411		53	13	358		NS
Yes		17		2	12	15	88
Menopausal status
Pre/peri-menopausal status		276		38	14	238		NS
Post menopausal status		146		15	10	131	90
T-stage
T1		196		22	11	174		NS
T2		214		31	14	183	86
T3		12		2	17	10	83
N-stage
N0		277		28	10	249		<0.05
N1		95		17	18	78	82
N2		32		4	13	28	88
N3		22		6	27	16	73
Pathology subtype
IDC		376		15	4	361		NS
ILC		7		1	14	6	86
IDC+ILC		12		1	8	11	92
Others		33		2	6	31	94
ER status
Negative		81		12	15	69		NS
Positive		340		43	13	297	87
PR status
Negative		121		12	10	109		NS
Positive		301		43	14	258	86
HER2
Negative		292		34	12	258		<0.05
Intermediate		31		1	3	30	97
Positive		104		20	19	84	81
Ki67
Negative		101		11	11	90		NS
Positive		303		39	13	264	87
Neoadjuvant chemotherapy
No		98		20	20	78		<0.05
Yes		328		35	11	293	89
Blood type
A		120		12	10	108		NS
B		108		20	19	88	81
O		172		20	12	152	88
AB		22		2	9	20	91
Chemotherapy regimens?
CMF		18		0	0	18		<0.01
CEF		21		1	5	20	95
EC		22		5	23	17	77
TC		53		1	2	52	98
DC		29		2	7	27	93
TEC		16		3	19	13	81
DEC		43		14	33	29	67
ET		78		11	14	67	86
ED		62		17	27	45	73
Others		7		1	14	6	86
Chemotherapy regimens with different risk of FN?.
Low	222		9		4	213		<0.01
Intermediate	101		15		15	86	85
High	105		31		30	74	70

BMI, body mass index. BSA, body surface area ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; FN, febrile neutropenia.?High risk regimen(DEC, DE); Intermediate risk regimen (TEC,ET OTHERS); ?C, Cyclophosphomide;M, Methotrexate; E, epirubicin; F, 5-Fluorouracil; T, Paclitaxle; D, Docetaxel;Others included regimens contained herceptins cisplatin, or nolvelbine; NS, non-significant;